CD274 and non-small cell lung carcinoma: National Comprehensive Cancer Network (NCCN) guidelines recommend molecular testing for these actionable biomarkers, preferably as a part of broad molecular profiling including PD‐L1 testing for patients with advanced or metastatic non‐squamous NSCLC.4